Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2109 | Late-Dexamethasone Wiki | 0.71 |
| drug2108 | Late dexamethazone Wiki | 0.71 |
| drug452 | BCG Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000370 | Ageusia NIH | 0.50 |
| D003110 | Colonic Neoplasms NIH | 0.35 |
| D000857 | Olfaction Disorders NIH | 0.16 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000224 | Hypogeusia HPO | 0.50 |
| HP:0003003 | Colon cancer HPO | 0.35 |
| HP:0000458 | Anosmia HPO | 0.16 |
Navigate: Correlations HPO
There are 2 clinical trials
Time to recover of Anosmia and / or ageusia and early corticosteroid use
Description: Time to recovery from anosmia and / or agusia
Measure: Time to recovery Time: one to 6 weeksTiming of of corticosteroids administration is very important in COVID19 cases for the recovery and decrease the mortality.
Description: Deterioration in the clinical picture of cases that necessitate hospitalization
Measure: Percentage of cases that will need hospitalization Time: one to two weeksDescription: Percentage of cases whose clinical status deteriorate to acute respiratory distress syndrome
Measure: Percentage of cases that deteriorate to acute respiratory distress syndrome Time: one to two weeksDescription: Percentage of cases with increased d-dimer from baseline level
Measure: Percentage of cases with increased d-dimer Time: two weeksDescription: Time to recovery of diarrhea
Measure: Time to recovery of diarrhea Time: one to two weeksDescription: Percentage reduction in CRP from baseline
Measure: Percentage reduction in CRP Time: one to four weeksDescription: Percentage reduction in LDH from baseline
Measure: Percentage reduction in LDH Time: one to four weeksDescription: Percentage reduction in ALT from baseline
Measure: Percentage reduction in ALT Time: one to four weeksDescription: Percentage reduction in Ferritin from baseline
Measure: Percentage reduction in Ferritin Time: one to four weeksDescription: Time to recovery of lymphopenia
Measure: Time to recovery of lymphopenia Time: one to two weeksDescription: Time to recovery of cough
Measure: Time to recovery of cough Time: one to two weeksDescription: Time to recovery of fever
Measure: Time to recovery of fever Time: one to two weeksDescription: Time to recovery of myalgia
Measure: Time to recovery of myalgia Time: one to two weeksDescription: Time to recovery of anosmia
Measure: Time to recovery of anosmia Time: one to six weeksDescription: Time to recovery of dyspnea
Measure: Time to recovery of dyspnea Time: one to two weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports